tetradecanoylphorbol acetate and Adenocystic Carcinoma

tetradecanoylphorbol acetate has been researched along with Adenocystic Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fässler, R; Khochbin, S; Masoumi, KC; Massoumi, R; Wickström, SA	1

Other Studies

1 other study(ies) available for tetradecanoylphorbol acetate and Adenocystic Carcinoma

Article	Year
CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. The EMBO journal, 2010, Jan-06, Volume: 29, Issue:1 Topics: Acetylation; Animals; Carcinoma, Adenoid Cystic; Catalytic Domain; Cell Cycle; Cell Line, Tumor; Cytokinesis; Deubiquitinating Enzyme CYLD; Genes, Tumor Suppressor; Histone Deacetylase 6; Histone Deacetylases; Humans; Keratinocytes; Melanocytes; Melanoma; Mice; Microtubules; Mutation; Recombinant Fusion Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Tubulin; Tumor Suppressor Proteins	2010

Article

Year

CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.

The EMBO journal, 2010, Jan-06, Volume: 29, Issue:1

Topics: Acetylation; Animals; Carcinoma, Adenoid Cystic; Catalytic Domain; Cell Cycle; Cell Line, Tumor; Cytokinesis; Deubiquitinating Enzyme CYLD; Genes, Tumor Suppressor; Histone Deacetylase 6; Histone Deacetylases; Humans; Keratinocytes; Melanocytes; Melanoma; Mice; Microtubules; Mutation; Recombinant Fusion Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Tubulin; Tumor Suppressor Proteins

2010